{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:42:26Z","timestamp":1791258146108,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005625","name":"RSNA Research and Educational Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115386","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T05:37:38Z","timestamp":1742794658000},"page":"115386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp"],"prefix":"10.1016","volume":"220","author":[{"given":"Volkan","family":"Beylergil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binsheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaad E.","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1322-0710","authenticated-orcid":false,"given":"Laurent","family":"Dercle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115386_bib1","doi-asserted-by":"crossref","first-page":"7952","DOI":"10.1038\/s41598-017-08310-5","article-title":"Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence","volume":"7","author":"Dercle","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2025.115386_bib2","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejca.2025.115386_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10384-019-00656-9","article-title":"Clinical predictors of survival in metastatic uveal melanoma","volume":"63","author":"Lorenzo","year":"2019","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ejca.2025.115386_bib4","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115386_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000146","article-title":"Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis","volume":"8","author":"Mulkey","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115386_bib6","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.115386_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","article-title":"Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis","volume":"19","author":"Beaver","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115386_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/annonc\/mdv550","article-title":"Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies","volume":"27","author":"Postel-Vinay","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115386_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115386_bib10","unstructured":"FDA. Project Optimus. 2023."},{"key":"10.1016\/j.ejca.2025.115386_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005924","article-title":"Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy","volume":"11","author":"Sivapalan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115386_bib12","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115386_bib13","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-19-2942","article-title":"Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics","volume":"26","author":"Dercle","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115386_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamaoncol.2021.6818","article-title":"Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis","volume":"8","author":"Dercle","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.115386_bib15","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1016\/j.annonc.2022.07.854","article-title":"728O - Results from phase I dose escalation of IMC-F106C, the first PRAME \u00d7\u2009CD3 ImmTAC bispecific protein in solid tumors","volume":"33","author":"Hamid","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115386_bib16","first-page":"1","article-title":"Vol-PACT: a foundation for the nih public-private partnership that supports sharing of clinical trial data for the development of improved imaging biomarkers in oncology","author":"Dercle","year":"2018","journal-title":"JCO Clin Cancer Inf"},{"key":"10.1016\/j.ejca.2025.115386_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2016.05.031","article-title":"Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1\/-L1 therapy","volume":"65","author":"Dercle","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115386_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112728","article-title":"Prognostic Implications of MRI Melanin Quantification and Cytogenetic Abnormalities in Liver Metastases of Uveal Melanoma","volume":"13","author":"Ramtohul","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.115386_bib19","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115386_bib20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdz108","article-title":"Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers","volume":"30","author":"Trebeschi","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115386_bib21","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1007\/s00330-018-5933-x","article-title":"Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab","volume":"29","author":"Durot","year":"2019","journal-title":"Eur Radiol."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:48:38Z","timestamp":1760640518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":21,"alternative-id":["S0959804925001674"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115386","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115386"}}